文献速递心律失常

靶向长QT综合征2型转运缺陷:一项2期临床研究及患者特异性细胞验证

Targeting trafficking defects in long QT syndrome type 2: a phase 2 clinical study with patient-specific cellular validation.
PubMed 文献 · Eur Heart J · 2026-09-22

结果显示lumacaftor显著缩短QTc(P < .001),人均变化31 ± 21 ms,基线QTc ≥500 ms者75%实现≥40 ms降低;无室性心律失常发生,不良反应主要为自限性胃肠道反应。患者特异性hiPSC-CMs中lumacaftor在5种变异中的3种恢复了hERG转运,与临床观察一致。

要点

  • Lumacaftor短期治疗可显著缩短LQT2转运缺陷患者的QTc。
  • 基线QTc ≥500 ms患者获益最明显,75%实现≥40 ms降低。
  • 细胞模型与临床结果部分一致,支持机制导向的变异特异性策略。

核心结论

  • 短期lumacaftor治疗在携带转运缺陷的LQT2患者中安全,并产生显著QTc缩短。
  • 细胞与临床结果的一致性支持在遗传性心律失常综合征中开展转运校正策略的精准医学框架。

研究设计与样本

  • 参与者住院接受lumacaftor治疗7天,期间持续遥测,通过系列心电图和12导联Holter量化QTc。
  • 对前5例携带不同基因变异的患者生成hiPSC-CMs,评估hERG成熟与转运。

主要发现

  • Lumacaftor整体产生显著QTc缩短(P < .001),人均变化为31 ± 21 ms。
  • 基线QTc ≥500 ms的患者效应最显著,75%实现QTc降低≥40 ms。
  • 未发生室性心律失常,不良反应主要为胃肠道且呈自限性。
  • 在hiPSC-CMs中,lumacaftor在5种变异中的3种恢复了hERG转运,与临床观察一致。

临床怎么用

  • 对于携带转运缺陷型KCNH2变异的LQT2患者,短期lumacaftor治疗可显著缩短QTc,尤其基线QTc ≥500 ms者获益更明显。
  • 治疗期间需监测胃肠道不良反应,但本研究中未见室性心律失常,安全性较好。
  • 患者特异性hiPSC-CMs验证支持基于基因变异机制选择转运校正治疗的精准医学思路。

局限性

  • 细胞机制验证仅覆盖前5例患者及5种变异,与临床结果仅部分一致。
  • 随访时间短(治疗7天),长期疗效与安全性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: A major component of long QT syndrome (LQTS) is LQT2 due to pathogenic variants in KCNH2, which frequently cause trafficking defects. Despite progress in therapeutic management, there is an unmet clinical need for mechanism-targeted therapies. It has been previously shown, using patient-specific human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), that lumacaftor (LUM), currently used for cystic fibrosis, can partially correct hERG trafficking. A single-arm phase 2 study was conducted to determine whether LUM could shorten QTc in LQT2 patients with trafficking defects. METHODS: Sixteen adult patients with genetically confirmed trafficking-defective KCNH2 variants were enrolled. Participants were admitted to hospital and received LUM for 7 days under continuous telemetry. QTc was quantified on serial electrocardiograms and 12-lead Holter recordings. For mechanistic correlation, hiPSC-CMs were generated from the first five participants with distinct genetic variants and assessed for hERG maturation and trafficking. RESULTS: Overall, lumacaftor produced a significant QTc shortening (P < .001). The per-patient change averaged 31 ± 21 ms. Patients with baseline QTc ≥500 ms exhibited the most substantial effect, with 75% achieving reductions ≥40 ms. No ventricular arrhythmias occurred, and adverse effects were primarily gastrointestinal and self-limited. In hiPSC-CMs, LUM restored hERG trafficking in three out of five variants, mirroring the clinical observations. CONCLUSIONS: Short-term LUM therapy is safe and yields a significant QTc shortening in LQT2 patients with a trafficking defect. Concordance between cellular and clinical findings reinforces the value of a mechanism-based, variant-informed approach and supports the feasibility of trafficking-correction strategies within a precision-medicine framework for inherited arrhythmia syndromes.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Crotti L, Dagradi F, Mura M, et al. Targeting trafficking defects in long QT syndrome type 2: a phase 2 clinical study with patient-specific cellular validation. Eur Heart J. 2026. PMID: 42771720. doi:10.1093/eurheartj/ehag753

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。